<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02907749</url>
  </required_header>
  <id_info>
    <org_study_id>Yang-20160905</org_study_id>
    <nct_id>NCT02907749</nct_id>
  </id_info>
  <brief_title>Spironolactone on Fibrosis Progrssion-Portal Hypertension(FP-PH)in Cirrhosis</brief_title>
  <acronym>FP-PH</acronym>
  <official_title>Effects of Spironolactone on Fibrosis Progression and Portal Pressure in Patients With Advanced Chronic Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changqing Yang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Tongji Hospital, Tongji University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the effects of spironolactone on liver fibrosis&#xD;
      progression and portal pressure gradient in patients with advanced chronic liver disease.&#xD;
      Eligible cirrhosis patients were 2:1 randomized to either combination (carvedilol and&#xD;
      spironolactone) or single (carvedilol) therapy group. Changes in virtual portal pressure&#xD;
      gradient (vPPG) of portal trunk (calculated based on reconstructed 3D model and measured&#xD;
      blood flow velocity), liver stiffness measurement (Fibroscan) and serum markers of liver&#xD;
      fibrogenesis were documented at baseline and six months later.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">July 31, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Virtual portal pressure gradient(vPPG)</measure>
    <time_frame>6 months</time_frame>
    <description>Calculated based on reconstructed 3D portal trunk using anatomical information extracted from CT angiography and blood flow velocity measured by Doppler ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver stiffness measurement (LSM)</measure>
    <time_frame>6 months</time_frame>
    <description>Detected using FibroScan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of portal hypertension-related complications</measure>
    <time_frame>6 months</time_frame>
    <description>variceal bleeding, ascites, hepatic encephalopathy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carvedilol starts at 6.25mg/d and increases to 12.5mg/d in next week as a maintainence dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spironolactone and carvedilol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carvedilol starts at 6.25mg/d and increases to 12.5mg/d in next week as a maintainence dose&#xD;
Spironolactone is added after carvedilol being tolerated, which starts with 20mg/d and increases to 40mg/d as a maintainence dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone and carvedilol</intervention_name>
    <description>Patients are treated with carvedilol in combination with spironolactone.</description>
    <arm_group_label>Carvedilol</arm_group_label>
    <other_name>Combination therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>Patients are treated with carvedilol only.</description>
    <arm_group_label>Spironolactone and carvedilol</arm_group_label>
    <other_name>Single therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -Proven cirrhosis based on histology or unequivocal clinical, sonographic and laboratory&#xD;
        findings&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with Î²-blockers or diuretics in the last 3 months&#xD;
&#xD;
          -  Severe cardiopulmonary or renal insufficiency&#xD;
&#xD;
          -  Chronic alcohol abuse&#xD;
&#xD;
          -  Can't tolerate side effects of oral carvedilol or spironolactone&#xD;
&#xD;
          -  History of variceal bleeding&#xD;
&#xD;
          -  Malignancy&#xD;
&#xD;
          -  Portal vein thrombosis&#xD;
&#xD;
          -  History of partial splenic embolization or splenectomy&#xD;
&#xD;
          -  Moderate or tense ascites&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Li, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Tongji Hospital, Tongji University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Tongji Hospital, Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>20065</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 13, 2016</study_first_submitted>
  <study_first_submitted_qc>September 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>August 21, 2020</last_update_submitted>
  <last_update_submitted_qc>August 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Tongji Hospital, Tongji University School of Medicine</investigator_affiliation>
    <investigator_full_name>Changqing Yang</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

